BrightAccountsProduction v1.0.0 v1.0.0 2023-11-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principal activity of the company is that of pharmaceutical contract manufacturing and the reasearch & development of medicinal product formulations. 31 October 2025 0 0 11555156 2024-10-31 11555156 2023-10-31 11555156 2022-10-31 11555156 2023-11-01 2024-10-31 11555156 2022-11-01 2023-10-31 11555156 uk-bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 11555156 uk-curr:PoundSterling 2023-11-01 2024-10-31 11555156 uk-bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 11555156 uk-bus:FullAccounts 2023-11-01 2024-10-31 11555156 uk-core:ShareCapital 2024-10-31 11555156 uk-core:ShareCapital 2023-10-31 11555156 uk-core:SharePremium 2024-10-31 11555156 uk-core:SharePremium 2023-10-31 11555156 uk-core:RevaluationReserve 2024-10-31 11555156 uk-core:RevaluationReserve 2023-10-31 11555156 uk-core:RetainedEarningsAccumulatedLosses 2024-10-31 11555156 uk-core:RetainedEarningsAccumulatedLosses 2023-10-31 11555156 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-10-31 11555156 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2023-10-31 11555156 uk-bus:FRS102 2023-11-01 2024-10-31 11555156 uk-core:Buildings 2023-11-01 2024-10-31 11555156 uk-core:PlantMachinery 2023-11-01 2024-10-31 11555156 uk-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-11-01 2024-10-31 11555156 uk-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-10-31 11555156 uk-core:CurrentFinancialInstruments 2024-10-31 11555156 uk-core:CurrentFinancialInstruments 2023-10-31 11555156 uk-core:WithinOneYear 2024-10-31 11555156 uk-core:WithinOneYear 2023-10-31 11555156 uk-core:WithinOneYear 2024-10-31 11555156 uk-core:WithinOneYear 2023-10-31 11555156 uk-core:WithinOneYear 2024-10-31 11555156 uk-core:WithinOneYear 2023-10-31 11555156 uk-core:AfterOneYear 2024-10-31 11555156 uk-core:AfterOneYear 2023-10-31 11555156 uk-core:AfterOneYear 2024-10-31 11555156 uk-core:AfterOneYear 2023-10-31 11555156 uk-core:BetweenOneTwoYears 2024-10-31 11555156 uk-core:BetweenOneTwoYears 2023-10-31 11555156 uk-core:BetweenTwoFiveYears 2024-10-31 11555156 uk-core:BetweenTwoFiveYears 2023-10-31 11555156 uk-core:BetweenOneFiveYears 2024-10-31 11555156 uk-core:BetweenOneFiveYears 2023-10-31 11555156 uk-core:EmployeeBenefits 2023-10-31 11555156 uk-core:EmployeeBenefits 2023-11-01 2024-10-31 11555156 uk-core:AcceleratedTaxDepreciationDeferredTax 2024-10-31 11555156 uk-core:TaxLossesCarry-forwardsDeferredTax 2024-10-31 11555156 uk-core:OtherDeferredTax 2024-10-31 11555156 uk-core:RevaluationPropertyPlantEquipmentDeferredTax 2024-10-31 11555156 uk-core:EmployeeBenefits 2024-10-31 11555156 2023-11-01 2024-10-31 11555156 uk-bus:Director1 2023-11-01 2024-10-31 11555156 uk-bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
GMP Manufacturing Ltd
 
Unaudited Financial Statements
 
for the financial year ended 31 October 2024



GMP Manufacturing Ltd
Company Registration Number: 11555156
BALANCE SHEET
as at 31 October 2024

2024 2023
Notes £ £
 
Fixed Assets
Intangible assets 4 1,909,755 -
Tangible assets 5 9,722,271 8,799,999
───────── ─────────
Fixed Assets 11,632,026 8,799,999
───────── ─────────
 
Current Assets
Stocks 6 758,772 422,347
Debtors 7 1,579,039 1,987,986
Cash at bank and in hand 150 144,272
───────── ─────────
2,337,961 2,554,605
───────── ─────────
Creditors: amounts falling due within one year 8 (5,016,403) (3,199,224)
───────── ─────────
Net Current Liabilities (2,678,442) (644,619)
───────── ─────────
Total Assets less Current Liabilities 8,953,584 8,155,380
 
Creditors:
amounts falling due after more than one year 9 (1,420,676) (70,150)
 
Provisions for liabilities 11 (1,790,171) (1,953,069)
───────── ─────────
Net Assets 5,742,737 6,132,161
═════════ ═════════
 
Capital and Reserves
Called up share capital 1 1
Share premium account 12 200,000 -
Revaluation reserve 12 5,164,748 5,859,206
Retained earnings 12 377,988 272,954
───────── ─────────
Equity attributable to owners of the company 5,742,737 6,132,161
═════════ ═════════
 

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).

           
The company has taken advantage of the exemption under section 444 not to file the Profit and Loss Account and Directors' Report.
           
For the financial year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Board and authorised for issue on 31 October 2025 and signed on its behalf by
           
           
________________________________          
Mr G George          
Director          
           



GMP Manufacturing Ltd
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 October 2024

   
1. General Information
 
GMP Manufacturing Ltd is a company limited by shares incorporated and registered in England. The registered number of the company is 11555156. The registered office of the company is Marfleet House, Valletta Street, Hull, HU9 5NP, United Kingdom. The principal activity of the company is that of pharmaceutical contract manufacturing and the reasearch & development of medicinal product formulations. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance

The financial statements of the company for the financial year ended 31 October 2024 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.

 
Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Intangible assets
 
Research & Development
Research & Development is valued at cost less accumulated amortisation.
 
Tangible assets and depreciation
Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
 
  Short leasehold property - 5% Straight line
  Plant, machinery & equipment - 10%, 20% & 33% Straight line
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
Leasing and hire purchases
Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.
 
Stocks
Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition.  Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Borrowing costs
Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
 
Provisions
Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.
 
Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Research and development
Development expenditure is written off in the same financial year unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period from which the company is expected to benefit.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
       
3. Employees
 
The average monthly number of employees, including directors, during the financial year was 38, (2023 - 32).
       
4. Intangible assets
  Development  
  Costs Total
  £ £
Cost
At 1 November 2023 - -
Additions 1,909,755 1,909,755
  ───────── ─────────
At 31 October 2024 1,909,755 1,909,755
  ───────── ─────────
Net book value
At 31 October 2024 1,909,755 1,909,755
  ═════════ ═════════
         
5. Tangible assets
  Short Plant, Total
  leasehold machinery  
  property & equipment  
  £ £ £
Cost or Valuation
At 1 November 2023 2,039,001 6,760,999 8,800,000
Additions 103,782 2,064,265 2,168,047
  ───────── ───────── ─────────
At 31 October 2024 2,142,783 8,825,264 10,968,047
  ───────── ───────── ─────────
Depreciation
At 1 November 2023 1 - 1
Charge for the financial year 187,665 1,058,110 1,245,775
  ───────── ───────── ─────────
At 31 October 2024 187,666 1,058,110 1,245,776
  ───────── ───────── ─────────
Net book value
At 31 October 2024 1,955,117 7,767,154 9,722,271
  ═════════ ═════════ ═════════
At 31 October 2023 2,039,000 6,760,999 8,799,999
  ═════════ ═════════ ═════════
       
6. Stocks 2024 2023
  £ £
 
Finished goods and goods for resale 758,772 422,347
  ═════════ ═════════
 
The replacement cost of stock did not differ significantly from the figures shown.
       
7. Debtors 2024 2023
  £ £
 
Trade debtors 1,124,162 1,631,827
Amounts owed by connected parties (Note 13) 215,237 192,620
Other debtors 76,607 -
Directors' current accounts 17,188 16,652
Taxation  (Note 10) 145,845 145,845
Prepayments and accrued income - 1,042
  ───────── ─────────
  1,579,039 1,987,986
  ═════════ ═════════
       
8. Creditors 2024 2023
Amounts falling due within one year £ £
 
Bank loan 575,173 1,205,768
Net obligations under finance leases
and hire purchase contracts 213,777 33,121
Trade creditors 1,758,221 1,118,981
Amounts owed to connected parties (Note 13) 737,255 187,570
Taxation  (Note 10) 587,468 372,621
Other creditors 1,059,033 274,371
Accruals:
Pension accrual 3,771 4,092
Other accruals 81,705 2,700
  ───────── ─────────
  5,016,403 3,199,224
  ═════════ ═════════
       
9. Creditors 2024 2023
Amounts falling due after more than one year £ £
 
Bank loan 146,837 28,766
Finance leases and hire purchase contracts 1,273,839 41,384
  ───────── ─────────
  1,420,676 70,150
  ═════════ ═════════
 
Loans
Repayable in one year or less, or on demand (Note 8) 575,173 1,205,768
Repayable between one and two years 115,173 6,545
Repayable between two and five years 31,664 22,221
  ───────── ─────────
  722,010 1,234,534
  ═════════ ═════════
 
 
Net obligations under finance leases
and hire purchase contracts
Repayable within one year 213,777 33,121
Repayable between one and five years 1,273,839 41,384
  ───────── ─────────
  1,487,616 74,505
  ═════════ ═════════
       
10. Taxation 2024 2023
  £ £
 
Debtors:
Corporation tax 145,845 145,845
  ═════════ ═════════
Creditors:
VAT 355,537 298,319
PAYE / NI 231,931 74,302
  ───────── ─────────
  587,468 372,621
  ═════════ ═════════
         
11. Provisions for liabilities
 
The amounts provided for deferred taxation are analysed below:
 
  Capital Total Total
  allowances    
       
    2024 2023
  £ £ £
 
At financial year start 1,953,069 1,953,069 -
Charged to profit and loss (162,898) (162,898) 1,953,069
  ───────── ───────── ─────────
At financial year end 1,790,171 1,790,171 1,953,069
  ═════════ ═════════ ═════════
           
12. Reserves
  Share Revaluation Profit Total
  premium reserve and loss  
  account   account  
  £ £ £ £
 
At 1 November 2023 200,000 5,859,206 272,954 6,332,160
Transfer of realised profit - (857,356) 857,356 -
Revaluation reserve property deferred tax - 162,898 - 162,898
(Loss)/profit for the financial year - - (752,322) (752,322)
  ───────── ───────── ───────── ─────────
At 31 October 2024 200,000 5,164,748 377,988 5,742,736
  ═════════ ═════════ ═════════ ═════════
   
 
Share Premium Reserve
 
The amount carried forward is the premium that arose from the issue of shares in 2024.
 
       
13. Related party transactions
  Balance Balance
  2024 2023
  £ £
 
  215,237 192,620
  ───────── ─────────
 
The following amounts are due to other connected parties:
  2024 2023
  £ £
 
  737,255 187,570
  ═════════ ═════════
 
Net balances with other connected parties:
  2024 2023
  £ £
 
  (522,018) 5,050
  ═════════ ═════════
   
14. Post-Balance Sheet Events
 

On 27 January 2025, the company received an equity investment of £4,999,995 in exchange for 60,060 C Ordinary Shares and 240,240 C1 Preferred Shares.

This transaction took place after the company's financial year end of 31 October 2024 and therefore represents a non-adjusting event under the provisions of Section 32 of FRS 102 ("Events after the End of the Reporting Period").

Accordingly, no adjustments have been made to the amounts recognised in these financial statements.

The proceeds from the investment will be utilised to support manufacturing expansion and working-capital requirements during the financial year ending 31 October 2025.

No other significant events requiring disclosure have occurred between the reporting date and the date of approval of these financial statements.

       
15. Changes in Equity
 
Other Comprehensive Income 2024 2023
  £ £
 
Revaluation reserve unrealised movement on revaluation of property - 5,859,206
  ═════════ ═════════
       
16. Earnings before interest, tax, depreciation and amortisation 2024 2023
  £ £
 
Earnings before interest, tax, depreciation and amortisation 667,024 168,782
  ═════════ ═════════